47
Randomized trials identified
Included in a 2025 systematic review of PEA research across varied patient populations and outcomes.
Bortoletto et al., 2025
Clinical evidence review | Palmitoylethanolamide
PEA Pro
Clinical research, made clear.
A plain-English review of PEA research: pooled findings, individual trials, null results, and the limits that matter. Clean evidence. No inflated claims.
Key pooled finding
1.68
A 2023 meta-analysis pooled 11 double-blind randomized controlled trials involving 774 participants with chronic pain. Pain scores favored PEA over control.
SMD 1.68 | 95% CI 1.05 to 2.31 | p = 0.00001 | High between-study heterogeneity | Lang-Illievich et al., Nutrients, 2023.
Figures come from the cited publications. Effect sizes, percentages, and p-values are kept separate.
PEA has been studied in randomized human trials
Two reviews define the scale of the evidence. The underlying trials vary in population, formulation, dose, and outcome.
11
Double-blind trials pooled
Included in a 2023 meta-analysis of PEA for chronic pain.
Lang-Illievich et al., 2023
774
Participants in the meta-analysis
Trials lasted 2 to 12 weeks and used 400 to 1,200 mg of PEA per day.
Lang-Illievich et al., 2023
9
Publications reviewed here
Selected to show pooled evidence, individual trials, mixed findings, and a null result.
Source links included below
Important: These studies evaluated PEA ingredients and specific formulations, not Neurogan PEA Pro. Doses, formulations, populations, and study durations differ from this product.
How the evidence is organized
Reviews summarize multiple trials. Individual randomized trials test defined populations and outcomes. Challenge studies provide narrower evidence and should not be read as general consumer outcomes.
Systematic review or meta-analysis
Randomized human trial
Mechanistic or challenge study
Key findings in context
View reported effect sizes, changes, and p-values. Statistical significance does not show the size or practical importance of a result.
Nine publications, reviewed one by one
Each summary states what was studied, what was reported, and what limits the finding.
No studies in that category.
What the research means
Six points to understand before interpreting the results.
PEA is a naturally occurring fatty-acid compound
Your body makes palmitoylethanolamide. It also appears in foods such as eggs, soybeans, and peanuts. Researchers study it because levels can rise during tissue stress.
Micronization changes particle size
Raw PEA is waxy and poorly soluble. Micronization mills it into smaller particles, which is why many clinical studies use micronized or ultra-micronized forms.
The most developed research area is pain
The 2023 meta-analysis pooled 11 double-blind trials in 774 people with chronic pain. Pain scores favored PEA over control, with high variation between studies.
One acute trial reported differences from one to 2.5 hours
Across 217 tracked discomfort episodes, pain scores favored PEA at measured time points from one to 2.5 hours. By hours three and four, the difference was no longer evident.
Some biomarker findings were statistically significant
In one four-week blinded trial, sP-selectin fell 8% with PEA and rose 5% in the control group. Other selected markers also differed between groups.
Results were not positive in every trial
In a 12-week trial in 73 people with spinal cord injury neuropathic pain, PEA did not beat placebo. That result belongs beside the positive findings.
Two terms, decoded
- p-value
- A p-value asks: if there were really no effect, how surprising would results this strong be? Below 0.05 is the usual bar for “statistically significant.” Smaller p-values are stronger statistical evidence, but they do not tell you the size of the benefit by themselves.
- Double-blind, placebo-controlled
- Neither the participants nor the researchers know who received the test ingredient until the study ends. This design helps reduce bias.
Where the evidence is uncertain
The research includes null and mixed findings, varied formulations, and substantial differences between studies.
Null result
PEA did not beat placebo for spinal cord injury nerve pain
In a 12-week multicenter randomized double-blind placebo-controlled trial in 73 people, mean pain fell 0.4 points with PEA versus 0.7 points with placebo - numerically worse than placebo - at p = 0.46. No benefit was demonstrated.
Andresen et al., Pain, 2016 | PMID 27227691
Mixed result
Recovery biomarkers improved; soreness did not clearly change
In 28 trained men over a 72-hour recovery window, PEA lowered myoglobin and blood lactate (p < 0.05) and raised Akt phosphorylation - but it did not clearly reduce soreness or localized swelling. Biomarkers moved; soreness and swelling did not clearly change.
Mallard et al., Nutrients, 2020 | PMID 32106527
Mixed result
One pain subscale missed significance
In the diabetic peripheral neuropathic pain trial, several measured outcomes favored PEA at p ≤ 0.001 - but the evoked pain subscale did not, at p = 0.09. IL-6 and elevated CRP landed right at the threshold, p = 0.05.
Pickering et al., Inflammopharmacology, 2022 | PMID 36057884
Partial result
Not every inflammatory marker moved
sP-selectin separated clearly (-8% vs +5%, β = -11.5, p = 0.0078), and IL-1β (p = 0.0222) and IL-2 (p = 0.0492) shifted - but some primary markers did not significantly change. This was a biomarker study, not a health-outcome study.
Fessler et al., Journal of Nutrition, 2022 | PMID 36084236
Limitation
The pooled analysis had high heterogeneity
The 2023 meta-analysis reported a pooled effect (SMD 1.68, 95% CI 1.05 to 2.31, p = 0.00001) but also high heterogeneity between the included trials, and noted that the optimal dose and formulation remain unresolved. A big pooled number with wide variation underneath deserves less confidence than the headline suggests.
Lang-Illievich et al., Nutrients, 2023 | PMID 36986081
Limitation
“47 RCTs” is a map, not one merged result
The 2025 review is a narrative systematic review across diverse conditions - it counts and characterizes the trials, it does not pool them into a single product-specific effect size. It tells you the field is large; it does not tell you the size of any one benefit.
Bortoletto et al., Brain Behavior & Immunity - Health, 2025
Limitation
Single sites, specific formulations, specific populations
The knee study was single-site. The menstrual crossover used the Levagen+ formulation in acute menstrual pain, not general daily discomfort. The gut study measured an indirect permeability marker under an aspirin challenge - not general digestive health. Study conditions do not transfer automatically to everyday use.
Steels 2019 | Rao 2025 | Couch 2019
The big one
These are ingredient trials, not Neurogan trials
Every result on this page belongs to PEA as an ingredient and formulation class. None of these studies tested Neurogan PEA Pro. Several enrolled people with diagnosed medical conditions. Those studies are included to show the ingredient literature, not to suggest product use for those conditions.
Applies to all nine studies above
Review the original publications
Open each cited paper to examine its methods, results, and author conclusions.